ABSTRACT
OBJECTIVE: To evaluate the economical efficiency of 3 therapeutic regimens for hyperthyroidism. METHODS: Medical records of 564 hyperthyroid outpatients were selected from our hospital in 2016, and they were divided into group A (185 cases), group B(191 cases) and group C(188 cases) according to drug use. Group A received Thiamazole tablets 2-4 tablet, once asthecondition gradually reduce th amount to 0. 5-2 tablets orally; group B received Thiamazole tablets (cusage and dosage are the same as group A)+Yikang pills 6 g, bid orally; group C received Thiamazole tablets (cusage and dosage are the same as group A)+ Xiakucao tablets 6 tablets, bid orally. The treatment courses of 3 groups lasted for 10 months. Clinical efficacy the occurrence of ADR and recurrence were observed in 3 groups. The pharmacoeconomic cost-effectiveness analysis was adopted for the economic evaluation of 3 therapeutic regimens. RESULTS: The tolal response rates of group A, B, C were 94. 06％, 95. 29％, 95. 75％, respectively; total incidence of ADR were 11. 36％, 10. 48％, 10. 11％; there was no statistical significance (P>0. 05). No recurrence occurred in the 3 groups. The average cost of 3 groups were 633. 80, 3 548. 89, 3 596. 00 yuan, respectively. The cost of group A was the lowest. The results of sensitivity analysis were also that the cost of group A was the lowest. CONCLUSIONS: 3 therapeutic regimens show good therapeutic efficacy and safety for hyperthyroidism, among which thiamazole alone has relatively higher pharmacoeconomic significance.